New mediums of technology must be utilized correctly to reap full benefits.
Insights are the currency Medical Affairs trades in, so unlocking the potential to generate that currency should be a strategic priority before every meeting.
Event organizers regularly collect metrics from their participants, but what happens to all these data points when the event is over? Are the metrics collected even useful? Even the best information is worthless if it just sits in a spreadsheet and nobody looks at it.
In a recent survey, 75% of event organizers who responded said they needed help understanding the event data they collect. Many admit to being overwhelmed with the day-to-day management of events. It is important to point out that these challenges span across the various types of events within both R&D and Commercial.
According to Brent Dykes’ book on effective data storytelling, only 5% of companies collecting data are using it to take action. This is a huge, missed opportunity.
It’s important for organizers to create a metrics capture plan prior to events that aligns with their strategic business goals. Starting with the end in mind and planning for success through that lens is the only way to ensure goals and return on investment (ROI) objectives are met. More importantly, it provides opportunities for those analyzing metrics to suggest recommendations to refine activity design and reassure invested stakeholders that those goals, and the unique problems they’re trying to solve, were addressed.
Achieving this moves these activities from isolated one-offs to integrated key tactical assets in an overarching strategic plan. Furthermore, it's only when the layering of expertise, engagement technology, and metrics analysis happens that those insights, combined with context of the activity’s goals, become truly actionable.
Best practice in planning for success includes strategic business goals alignment sessions with content developers and content technology providers. Those calls should not only cover the objectives but drill down into the potential demographics of those attending the meetings to ensure a granular, meaningful view of the metrics later. For example, planning to capture and then analyze data by specialty, location, seniority, or even pre-determined opinions vastly improves the levers teams can pull when trying to unpick the insights lock.
Critical to data capture is involving content and technology teams earlier in planning, particularly in detailed slide reviews that reveal where engagement might be needed most based on what key messages you want the audience to retain. Presenters, who despite the best intentions may not have fully bought into the value that the metrics from their sessions provide, also need coaching to ensure the questions being asked of the audience land well.
Professional support during any event improves content engagement adoption and increases the metrics capture yield required for actionable insights to be generated. There is a wealth of content engagement platforms available now, but only some come with the talent needed to weave a metrics plan into the running order and look for last-minute engagement opportunities.
Add the variables of in-person, virtual, and hybrid audiences we now cater for, and that same team will need to understand the learning challenges each audience faces in its respective location and adjust accordingly. Active session monitoring helps with this, especially when many of the insights come from verbal conversations, particularly prevalent in advisory board settings.
With virtual and hybrid formats still relatively new (and necessary), stakeholders are looking for solutions that create an equally meaningful experience for onsite and offsite audiences, yet yield a consolidated and truly representative capture of engagement metrics to interpret into insights.
The Content Marketing Institute describes vanity metrics as “…easy to obtain in large numbers—all platforms supply them; it’s difficult because they are often ambiguous when it comes to reporting a return on investment or value to a business.”
In the case of meetings and events, vanity metrics reported are often how many people logged on or how many times a speaker biography was viewed. While these types of bland metrics have a place—and certainly for meetings, where there is regulatory compliance to report attendance—they only tell a fraction of the story and, critically, aren’t typically actionable.
The real value of engaging audiences with content, and measuring it, comes when the specific goals for that meeting type have been used as the lens through which actions are taken. Here is a sample of that value:
A single event only provides a snapshot in time of the art of the possible. Aggregating those snapshots can generate a unique source of reference to refine activity design, content effectiveness, attendee engagement or selection, and faculty performance, as well as arm stakeholders with evidence of continued activity outcomes success year-round.
Annual or quarterly reviews of the benchmarked insights from meetings and events is the key to unlocking a program's potential. This can be achieved either through API transfer of engagement-enriched data or structured insights workshops with key stakeholders and partners.
The next time you or someone in your organization is planning an important meeting, think about asking the following questions:
In summary, medical affairs, R&D, and commercial groups collect data across all their initiatives, but without the context of their activity’s goals can struggle to transform it into tangible insights resulting in lost innovation opportunities, poor medical community engagement, limited market intelligence, and ultimately budget risk.
Going the extra mile and leveraging combinations of content engagement technology, meaningful metrics, and flawless service, alongside industry knowledge and expertise, develops actionable insights that are proven to improve business outcomes.
Chris Bryant, vice president of analytics and insights management, Array
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.